{
    "Trade/Device Name(s)": [
        "Total Intact PTH ImmunoChemiluminoMetric (ICMA) Assay",
        "Total Intact Parathyroid Hormone (PTH) test system"
    ],
    "Submitter Information": "Scantibodies Laboratory, Inc.",
    "510(k) Number": "K060348",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEW"
    ],
    "Summary Letter Date": "February 7, 2006",
    "Summary Letter Received Date": "February 10, 2006",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1545"
    ],
    "Regulation Name(s)": [
        "Parathyroid hormone test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Parathyroid hormone"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "ImmunoChemiluminoMetric Assay (ICMA)"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Test System"
    ],
    "Document Summary": "FDA 510(k) summary for Scantibodies Laboratory Total Intact PTH ImmunoChemiluminoMetric (ICMA) Assay to measure parathyroid hormone in plasma.",
    "Indications for Use Summary": "Intended to measure parathyroid hormone in plasma to aid in the differential diagnosis of hypercalcemia and hypocalcemia due to disorders of calcium metabolism.",
    "fda_folder": "Clinical Chemistry"
}